India to treat homegrown COVID-19 vaccine same as AstraZeneca's

Administering Bharat Biotech's COVAXIN, a move cheered by nationalist politicians, has worried some health experts who consider it rushed, as the vaccine has only limited, "clinical-trial mode" approval. In addition to efficacy concerns, the close monitoring required for its use will be a massive challenge in a country of 1.35 billion people.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news